Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome

The JAPAN-ACS subanalysis study

Hiroaki Takashima, Yukio Ozaki, Takeshi Morimoto, Takeshi Kimura, Takafumi Hiro, Katsumi Miyauchi, Yoshihisa Nakagawa, Masakazu Yamagishi, Hiroyuki Daida, Tomofumi Mizuno, Kenji Asai, Yasuo Kuroda, Takashi Kosaka, Yasushi Kuhara, Akiyoshi Kurita, Kazuyuki Maeda, Tetsuya Amano, Masunori Matsuzaki

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: The JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome) trial showed that intensive statin therapy could induce significant coronary plaque regression in acute coronary syndrome (ACS). We evaluated the impact of metabolic syndrome (MetS) and its components on coronary plaque regression in the JAPAN-ACS patients. Methods and Results: Serial intravascular ultrasound measurements over 8-12 months were performed in 242 ACS patients receiving pitavastatin or atorvastatin. Patients were divided into groups according to the presence of MetS or the number of MetS components. Although the percent change in plaque volume (%PV) was not significantly different between the MetS (n=119) and non-MetS (n=123) groups (P=0.50), it was significantly associated with an increasing number of MetS components (component 0: -24.0%, n=7; components 1: -20.8%, n=31; components 2: -16.1%, n=69; components 3: -18.7%, n=83; components 4: -13.5%, n=52; P=0.037 for trend). The percent change in body mass index (%BMI) significantly correlated with %PV (r=0.15, P=0.021), especially in the MetS components 4 group (r=0.35, P=0.017). In addition, %BMI was an independent predictor of plaque regression after adjustment for the changes of low- and high-density lipoprotein cholesterol, triglycerides and HbA1c. Conclusions: The clustering of MetS components, but not the presence of MetS itself, could attenuate coronary plaque regression during intensive statin therapy in ACS patients. Therefore, to achieve a greater degree of plaque regression, it is necessary to treat to each MetS component and use lifestyle modification.

Original languageEnglish
Pages (from-to)2840-2847
Number of pages8
JournalCirculation Journal
Volume76
Issue number12
DOIs
Publication statusPublished - 10-12-2012

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Acute Coronary Syndrome
Cluster Analysis
Japan
Therapeutics
Atorvastatin Calcium
pitavastatin
HDL Cholesterol
Life Style
Triglycerides
Body Mass Index

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Takashima, Hiroaki ; Ozaki, Yukio ; Morimoto, Takeshi ; Kimura, Takeshi ; Hiro, Takafumi ; Miyauchi, Katsumi ; Nakagawa, Yoshihisa ; Yamagishi, Masakazu ; Daida, Hiroyuki ; Mizuno, Tomofumi ; Asai, Kenji ; Kuroda, Yasuo ; Kosaka, Takashi ; Kuhara, Yasushi ; Kurita, Akiyoshi ; Maeda, Kazuyuki ; Amano, Tetsuya ; Matsuzaki, Masunori. / Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome : The JAPAN-ACS subanalysis study. In: Circulation Journal. 2012 ; Vol. 76, No. 12. pp. 2840-2847.
@article{cfb66f4d25244dcaae30ae1c2d2705d8,
title = "Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: The JAPAN-ACS subanalysis study",
abstract = "Background: The JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome) trial showed that intensive statin therapy could induce significant coronary plaque regression in acute coronary syndrome (ACS). We evaluated the impact of metabolic syndrome (MetS) and its components on coronary plaque regression in the JAPAN-ACS patients. Methods and Results: Serial intravascular ultrasound measurements over 8-12 months were performed in 242 ACS patients receiving pitavastatin or atorvastatin. Patients were divided into groups according to the presence of MetS or the number of MetS components. Although the percent change in plaque volume ({\%}PV) was not significantly different between the MetS (n=119) and non-MetS (n=123) groups (P=0.50), it was significantly associated with an increasing number of MetS components (component 0: -24.0{\%}, n=7; components 1: -20.8{\%}, n=31; components 2: -16.1{\%}, n=69; components 3: -18.7{\%}, n=83; components 4: -13.5{\%}, n=52; P=0.037 for trend). The percent change in body mass index ({\%}BMI) significantly correlated with {\%}PV (r=0.15, P=0.021), especially in the MetS components 4 group (r=0.35, P=0.017). In addition, {\%}BMI was an independent predictor of plaque regression after adjustment for the changes of low- and high-density lipoprotein cholesterol, triglycerides and HbA1c. Conclusions: The clustering of MetS components, but not the presence of MetS itself, could attenuate coronary plaque regression during intensive statin therapy in ACS patients. Therefore, to achieve a greater degree of plaque regression, it is necessary to treat to each MetS component and use lifestyle modification.",
author = "Hiroaki Takashima and Yukio Ozaki and Takeshi Morimoto and Takeshi Kimura and Takafumi Hiro and Katsumi Miyauchi and Yoshihisa Nakagawa and Masakazu Yamagishi and Hiroyuki Daida and Tomofumi Mizuno and Kenji Asai and Yasuo Kuroda and Takashi Kosaka and Yasushi Kuhara and Akiyoshi Kurita and Kazuyuki Maeda and Tetsuya Amano and Masunori Matsuzaki",
year = "2012",
month = "12",
day = "10",
doi = "10.1253/circj.CJ-11-1495",
language = "English",
volume = "76",
pages = "2840--2847",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "12",

}

Takashima, H, Ozaki, Y, Morimoto, T, Kimura, T, Hiro, T, Miyauchi, K, Nakagawa, Y, Yamagishi, M, Daida, H, Mizuno, T, Asai, K, Kuroda, Y, Kosaka, T, Kuhara, Y, Kurita, A, Maeda, K, Amano, T & Matsuzaki, M 2012, 'Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: The JAPAN-ACS subanalysis study', Circulation Journal, vol. 76, no. 12, pp. 2840-2847. https://doi.org/10.1253/circj.CJ-11-1495

Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome : The JAPAN-ACS subanalysis study. / Takashima, Hiroaki; Ozaki, Yukio; Morimoto, Takeshi; Kimura, Takeshi; Hiro, Takafumi; Miyauchi, Katsumi; Nakagawa, Yoshihisa; Yamagishi, Masakazu; Daida, Hiroyuki; Mizuno, Tomofumi; Asai, Kenji; Kuroda, Yasuo; Kosaka, Takashi; Kuhara, Yasushi; Kurita, Akiyoshi; Maeda, Kazuyuki; Amano, Tetsuya; Matsuzaki, Masunori.

In: Circulation Journal, Vol. 76, No. 12, 10.12.2012, p. 2840-2847.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome

T2 - The JAPAN-ACS subanalysis study

AU - Takashima, Hiroaki

AU - Ozaki, Yukio

AU - Morimoto, Takeshi

AU - Kimura, Takeshi

AU - Hiro, Takafumi

AU - Miyauchi, Katsumi

AU - Nakagawa, Yoshihisa

AU - Yamagishi, Masakazu

AU - Daida, Hiroyuki

AU - Mizuno, Tomofumi

AU - Asai, Kenji

AU - Kuroda, Yasuo

AU - Kosaka, Takashi

AU - Kuhara, Yasushi

AU - Kurita, Akiyoshi

AU - Maeda, Kazuyuki

AU - Amano, Tetsuya

AU - Matsuzaki, Masunori

PY - 2012/12/10

Y1 - 2012/12/10

N2 - Background: The JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome) trial showed that intensive statin therapy could induce significant coronary plaque regression in acute coronary syndrome (ACS). We evaluated the impact of metabolic syndrome (MetS) and its components on coronary plaque regression in the JAPAN-ACS patients. Methods and Results: Serial intravascular ultrasound measurements over 8-12 months were performed in 242 ACS patients receiving pitavastatin or atorvastatin. Patients were divided into groups according to the presence of MetS or the number of MetS components. Although the percent change in plaque volume (%PV) was not significantly different between the MetS (n=119) and non-MetS (n=123) groups (P=0.50), it was significantly associated with an increasing number of MetS components (component 0: -24.0%, n=7; components 1: -20.8%, n=31; components 2: -16.1%, n=69; components 3: -18.7%, n=83; components 4: -13.5%, n=52; P=0.037 for trend). The percent change in body mass index (%BMI) significantly correlated with %PV (r=0.15, P=0.021), especially in the MetS components 4 group (r=0.35, P=0.017). In addition, %BMI was an independent predictor of plaque regression after adjustment for the changes of low- and high-density lipoprotein cholesterol, triglycerides and HbA1c. Conclusions: The clustering of MetS components, but not the presence of MetS itself, could attenuate coronary plaque regression during intensive statin therapy in ACS patients. Therefore, to achieve a greater degree of plaque regression, it is necessary to treat to each MetS component and use lifestyle modification.

AB - Background: The JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome) trial showed that intensive statin therapy could induce significant coronary plaque regression in acute coronary syndrome (ACS). We evaluated the impact of metabolic syndrome (MetS) and its components on coronary plaque regression in the JAPAN-ACS patients. Methods and Results: Serial intravascular ultrasound measurements over 8-12 months were performed in 242 ACS patients receiving pitavastatin or atorvastatin. Patients were divided into groups according to the presence of MetS or the number of MetS components. Although the percent change in plaque volume (%PV) was not significantly different between the MetS (n=119) and non-MetS (n=123) groups (P=0.50), it was significantly associated with an increasing number of MetS components (component 0: -24.0%, n=7; components 1: -20.8%, n=31; components 2: -16.1%, n=69; components 3: -18.7%, n=83; components 4: -13.5%, n=52; P=0.037 for trend). The percent change in body mass index (%BMI) significantly correlated with %PV (r=0.15, P=0.021), especially in the MetS components 4 group (r=0.35, P=0.017). In addition, %BMI was an independent predictor of plaque regression after adjustment for the changes of low- and high-density lipoprotein cholesterol, triglycerides and HbA1c. Conclusions: The clustering of MetS components, but not the presence of MetS itself, could attenuate coronary plaque regression during intensive statin therapy in ACS patients. Therefore, to achieve a greater degree of plaque regression, it is necessary to treat to each MetS component and use lifestyle modification.

UR - http://www.scopus.com/inward/record.url?scp=84870495078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870495078&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-11-1495

DO - 10.1253/circj.CJ-11-1495

M3 - Article

VL - 76

SP - 2840

EP - 2847

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 12

ER -